ADMA生物制品
ADMA
10.68
-0.05
-0.47%
ADMA生物制品
US · ADMA
#2705 按市值排名
上市于 1970
10.68
-0.05
-0.47%
实时 - 追踪5344个代码 - 心跳于193秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期(2026/Q3)披露持股的机构数量减少了2家。
- 机构持股总比例上升了0.4个百分点。
机构持股
- 机构持股比例
- 91.64% +0.40pp
- 机构数量
- 375 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份,同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund64.67%
Hedge Fund17.89%
Public Company3.43%
Individual/Insider1.89%
Private Company1.51%
Government Pension Fund1.50%
Family Office/Trust1.32%
VC/PE Fund1.11%
Other6.59%
主要股东 截至 2026-06-30
BlackRock
17.12% · 38.36M 股
State Street Global Advisors
7.64% · 17.12M 股
Vanguard Capital Management, LLC
5.25% · 11.76M 股
Vanguard Portfolio Management, LLC
4.50% · 10.09M 股
Rubric Capital Management LP
4.17% · 9.34M 股
Capital Research
3.91% · 8.76M 股
First Trust Advisors L.P.
3.48% · 7.80M 股
Geode Capital Management, LLC
2.71% · 6.06M 股
Caligan Partners, LP
2.56% · 5.73M 股
D. E. Shaw & Co., L.P.
2.35% · 5.27M 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Adam Grossman | Chief Executive Officer | 1.31% |
| Jerrold Grossman | Co-Founder & Vice Chairman of the Board | 0.25% |
| Young Kwon | Independent Director | 0.11% |
| Lawrence Guiheen | Independent Director | 0.08% |
| Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | 0.07% |
| Steven Elms | Independent Chairperson | 0.04% |
| Alison Finger | Director | 0.02% |
| Eduardo Salas | Director | 0.00% |
| Brad Tade | Vice President of Financial Operations | 0.00% |
| P. Terence Kohler | Chief Financial Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-23 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -3,177 | $8.37 |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Acquisition | +85,130 | -- |
| 2026-07-15 | P. Terence Kohler | Chief Financial Officer | Other Derivative Acquisition | +136,363 | $8.81 |
| 2026-05-26 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +6,400 | $7.91 |
| 2026-05-11 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-05-10 | Jerrold Grossman | Co-Founder & Vice Chairman of the Board | Open Market Acquisition | +12,500 | $8.01 |
| 2026-03-31 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -20,362 | $9.11 |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Derivative Exercise and Sale | -30,000 | -- |
| 2026-03-16 | Lawrence Guiheen | Independent Director | Other Acquisition | +30,000 | -- |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Automatic Disposition | -6,000 | $15.16 |
| 2026-03-15 | Adam Grossman | Chief Executive Officer | Derivative Exercise and Sale | -15,000 | $5.40–15.16 |
| 2026-03-09 | Brad Tade | Vice President of Financial Operations | Intent to Sell (Form 144) | -50,026 | $15.81 |
| 2026-03-08 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Other Disposition | -91,266 | -- |
| 2026-03-08 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Derivative Exercise and Sale | -10,096 | $1.55–15.63 |
| 2026-03-06 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -85,951 | $15.39 |
| 2026-03-06 | Kaitlin Kestenberg | Senior Vice President of Compliance & Project Operations | Sale to Issuer | -14,294 | $15.39 |
| 2026-03-05 | Aisling Capital Management LP | -- | Open Market Acquisition | +14,000 | $15.39–15.67 |
| 2026-02-25 | P. Terence Kohler | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -54,858 | $15.18 |
| 2026-02-18 | Adam Grossman | Chief Executive Officer | Sale to Issuer | -24,793 | $16.32 |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:19 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
ADMA生物制品 讨论区 0 条评论